Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
Pyxis Oncology, Inc. (NASDAQ:PYXS) announced on Thursday, a portfolio prioritization, focusing resources on advancing its lead clinical program, PYX-201.
Pyxis Oncology, Inc.（纳斯达克：PYXS）在周四宣布了一项投资组合优先级，专注于将资源用于推进其主要临床项目PYX-201。
Pyxis Oncology's second clinical program, PYX-106, is being deprioritized to allocate resources toward advancing the lead asset, PYX-201.
Pyxis Oncology的第二个临床项目PYX-106被降级优先级，以便将资源分配给推进主要资产PYX-201。
As a result, Pyxis Oncology has decided to suspend further clinical investment in PYX-106, which was in-licensed from Biosion Inc., with Biosion retaining rights for Greater China.
因此，Pyxis Oncology决定暂停对PYX-106的进一步临床投资，该项目是从Biosion Inc.引进的，Biosion保留大中华地区的权利。
Also Read: Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
另请阅读：Pyxis Oncology的癌症药物进展引发分析师关注
In November, Pyxis Oncology reported preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating its safety and efficacy in multiple solid tumor types.
在11月，Pyxis Oncology报告了PYX-201正在进行的I期剂量递增研究的初步数据，评估其在多种实体瘤类型中的安全性和有效性。
Among patients with HNSCC, PYX-201 achieved a confirmed 50% objective response rate (ORR), including one complete response and a disease control rate (DCR) of 100% in six heavily pretreated HPV-positive and HPV-negative evaluable patients with a median of four prior lines of therapy.
在HNSCC患者中，PYX-201的确认客观反应率（ORR）达到了50%，包括1例完全反应和6名经过重度治疗的HPV阳性和HPV阴性可评估患者的疾病控制率（DCR）为100%，中位数接受了四个前线治疗。
Across six solid tumor types of interest at therapeutically active dose levels, including HNSCC, ovarian, non-small cell lung cancer (NSCLC), HR+/HER2- breast cancer, triple-negative breast cancer (TNBC) and sarcoma, PYX-201 (n=31) achieved a 26% ORR in the Phase 1 trial, with dose-dependent responses observed.
在包括HNSCC、卵巢癌、非小细胞肺癌（NSCLC）、HR+/HER2-乳腺癌、三阴性乳腺癌（TNBC）和肉瘤在内的六种实体瘤类型的治疗有效剂量水平中，PYX-201（n=31）在I期试验中达到了26%的ORR，观察到剂量依赖性的反应。
The portfolio prioritization further supports a development plan for PYX-201 in several dose expansion studies, including monotherapy in 2/3L HNSCC, in combination with pembrolizumab in 1/2L+ HNSCC, and pembrolizumab combination studies in other solid tumors including HR+/HER2- and triple-negative breast cancer.
该投资组合优先级进一步支持PYX-201在多个剂量扩展研究中的开发计划，包括在2/3L HNSCC中的单药治疗、在1/2L+ HNSCC中与pembrolizumab的联合治疗，以及在其他实体瘤（包括HR+/HER2-和三阴性乳腺癌）中的pembrolizumab联合研究。
Preliminary data from these cohorts are expected in the second half of 2025 and the first half of 2026.
这些队列的初步数据预计将在2025年下半年和2026年上半年公布。
"Given the historical development challenges associated with anti-siglec-15 antibodies, we believe that the Street expectations were low heading into the initial data readout for PYX-106," said the William Blair analyst.
“鉴于与抗siglec-15抗体相关的历史开发挑战，我们相信在PYX-106的初步数据公布前，市场的预期较低，”威廉·布莱尔分析师说。
The company's current cash position is expected to fund its planned monotherapy and combination therapy trials of PYX-201 into the second half of 2026.
公司目前的现金状况预计将支持其计划中的PYX-201单药治疗和联合疗法试验，直到2026年下半年。
The analyst says it supports management's decision to stop investing in the program. While PYX-201 showed some activity, it likely won't significantly change head and neck cancer treatment.
分析师表示，这支持管理层停止对该项目进行投资的决定。虽然PYX-201显示出一些活性，但它可能不会显著改变头颈癌的治疗。
PYXS Price Action: PYXS Oncology stock is up 1.30% at $1.56 at publication Friday.
PYXS股价动态：公开时PYXS癌症股票上涨1.30%，报$1.56。
- Why Is Cancer-Focused Aadi Bioscience Stock Trading Higher On Friday?
- 为什么癌症专注的Aadi生物科技股票在星期五交易更高？
This image was created using artificial intelligence MidJourney.
此图像是使用人工智能MidJourney创建的。
